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Objectives: Heart function is variably impaired after cardiopulmonary bypass. We
hypothesized that, similar to other myocardial injury states, cardiopulmonary
bypass leads to enhanced activity of nitric oxide synthase and matrix metallopro-
teinases.
Methods: We obtained right atrial biopsy specimens and plasma samples at the
onset and termination of cardiopulmonary bypass in 10 patients. Biopsy specimens
were analyzed for nitric oxide synthase activity by using a citrulline assay, where-
as plasma and tissue were analyzed for matrix metalloproteinase-9 and matrix me-
talloproteinase-2 activity by using zymography. Tissue inhibitor of metallopro-
teinase-4 was analyzed by means of Western blotting. The cellular expression of
inducible nitric oxide, endothelial nitric oxide synthase, matrix metalloproteinase-
2, and matrix metalloproteinase-9 was determined in right atrial biopsy samples
from 3 additional patients by using the appropriate conjugated antibodies.
Results: Nitric oxide synthase activity increased from the beginning to the end of
bypass (4.46 ± 1.07 vs 16.77 ± 4.86 pmol citrulline/mg of protein per minute,
respectively; P = .018). Pro-matrix metalloproteinase-9 activity increased in hearts
(199 ± 41 vs 660 ± 177 density units/mg protein; P = .008) and plasma (14.1 ± 4.6
vs 52.2 ± 5.9 density units/mg protein; P = .008). Pro-matrix metalloproteinase-2
activity increased in the heart (201 ± 23 vs 310 ± 35 density units/mg protein, P <
.05) but not in plasma. Tissue inhibitor of metalloproteinase-4 expression in the
heart decreased (1574 ± 280 vs 864 ± 153 density units, P = .014).
Conclusions: Cardiopulmonary bypass activates enzymes mediating acute inflam-
mation and organ injury (ie, nitric oxide synthase, matrix metalloproteinase-9, and
matrix metalloproteinase-2). Decreased tissue inhibitor of metalloproteinase-4
expression allows relatively unopposed increases in matrix metalloproteinase tissue
activity. We postulate that these changes play a role in the pathogenesis of heart dys-
function after bypass surgery.
Advances in cardiopulmonary bypass (CPB) have allowed coronaryartery bypass grafting (CABG) to become a common surgicalprocedure worldwide.1,2 Proinflammatory cytokines are releasedduring CPB,3 and these cytokines are known to activate down-stream signaling, leading to the generation and release of otherinflammatory mediators. We have measured activities of 2 fami-
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lies of inflammatory enzymes, nitric oxide synthases (NOS)
and matrix metalloproteinases (MMPs), specifically MMP-
9 and MMP-2. We have selected to study NOS4 and these
MMPs5 of many inflammatory mediators released during
CABG because increases in their respective activities have
been associated with decrements in cardiac function in
human patients. We have previously shown, in a canine
model, that CPB causes increased NOS activity in cardiac
tissue, and this increase was associated with impaired
hemodynamics.6 We have now examined changes of MMP-
2, MMP-9, and NOS in human cardiac tissue during CABG.
To understand the biologic significance of any changes in
MMP activity, we concurrently analyzed the expression of
tissue inhibitor of MMP-4 (TIMP-4), an endogenous regu-
lator of MMP activity in vivo7 and the MMP inhibitor pref-
erentially expressed in adult heart tissue.5
Materials and Methods
The University of Saskatchewan Ethics Committee approved
this study. Ten patients undergoing elective CABG (Table 1)
were selected by convenience sampling. We obtained informed
consent from all subjects. Intraoperative and postoperative
management was not standardized but was left to the treating
physicians. In general, blood cardioplegia (BCD4; Sharely,
Anaheim, Calif) was commenced, initially with 30 mEq of KCl
and subsequently decreasing the concentration to 10 mEq of
KCl every 10 minutes or with evidence of electrical activity. All
patients had arterial and venous blood samples drawn at the
time of anesthetic induction, at the initiation of CPB, at termi-
nation of CPB, and 1 hour after return to the intensive care unit.
Intraoperative measurements included aortic crossclamp time,
total CPB time, and number of vessels grafted. Hemodynamic
measurements included mean systemic blood pressure, pul-
monary artery pressure, pulmonary capillary wedge pressure,
and cardiac index. Blood samples were analyzed for blood
gases, including oxyhemoglobin saturation, complete blood cell
counts and differential, creatine phosphokinase MB fraction,
and MMP activity (see below). At initiation of CPB and just
before termination of CPB, strip biopsy samples (approximate-
ly 0.5 cm × 0.5 cm) of the right atrium distal to the site of can-
nula insertion were obtained concurrent with blood sampling.
Cell-free plasma obtained by means of blood centrifugation at
2000g for 5 minutes at room temperature and the biopsy speci-
mens were snap frozen with liquid nitrogen and were stored at
–80°C for subsequent analysis.
MMP activity in plasma and in the homogenates of cardiac tis-
sue was measured ex vivo by using zymography, as previously
described.8-10 Briefly, MMP-2 and MMP-9 were identified by their
molecular weight when compared with standards, gelatinolytic
activity, and the susceptibility to inhibition with MMP inhibitors.
Enzyme activity was assayed by using densitometric analysis of
gelatinolytic bands.8-10 The expression of cardiac TIMP-4 was
measured with Western blotting.11 Samples were probed with
polyclonal antibodies against TIMP-4 (0.2 µg/mL; Chemicon
International, Temecula, Calif). Anti-mouse IgG peroxidase conju-
gate developed in sheep was used as a secondary antibody (Sigma,
St Louis, Mo). The detection of protein bands was carried out with
an ECL detection kit (Amersham, Oakville, Ontario, Canada).
Cardiac NOS activity was measured by the rate of conversion
of U-14C-L-arginine to U-14C-L-citrulline, as previously described
and validated by our group.9 Briefly, samples were incubated with
U-14C-L-arginine in assay buffer9 in the presence or absence of 1.5
mmol/L NG-monomethyl-L-arginine to determine NOS-dependent
L-citrulline formation. Etyleneglycol-bis-(β-aminoethylether)-
N,N,N’,N’-tetraacetic acid (2 mmol/L), a calcium-chelating agent,
was used to differentiate between Ca2+-dependent and Ca2+-inde-
pendent activity.9 After 20 minutes of incubation, the reaction was
terminated by means of dilution and removal of nonreacted L-argi-
nine with AG50W-X8 resin (Bio-Rad), and the remaining radioac-
tivity was counted and taken for calculation of NOS activity.
These biopsy samples were too small to allow us to obtain con-
current evaluation with immunohistochemistry. Therefore after the
initial 10 patients completed this protocol, we obtained strip biop-
sy samples from a further 5 patients at time points identical to
those described above. These samples were immediately placed in
buffered formalin and then embedded in paraffin. We obtained 4-
to 5-µm sections from the paraffin blocks of the formalin-fixed
cardiac tissue biopsy specimens. We obtained hematoxylin and
eosin–stained sections and performed immunoperoxidase tests on
the basis of the streptavidin-biotin method. Briefly, samples were
prepared by mounting 4-µm thick slices of formalin-fixed paraffin-
embedded heart sections onto Aptex-coated slides and then drying
them overnight at 37°C. Staining of the slides was completed after
10 minutes of heating at 70°C, deparaffinization with xylene, and
rehydration with decreasing grades of ethanol ending with water.
Slides were next soaked in H2O2/methanol solution for 6 minutes
and later rinsed with water to block endogenous peroxidase.
Antigen retrieval was accomplished by microwaving slides in cit-
rate buffer. Counterstaining was done with Harris’ Haematoxylin.
Blocking reagent (20% normal goat serum) was applied to each
slide, followed by 15 minutes of incubation at room temperature.
Primary antisera consisted of mouse anti-human monoclonal anti-
bodies for endothelial NOS (eNOS) and inducible NOS (iNOS; 5
µg/mL; Transduction Laboratories, Lexington, Ky), as well as
polyclonal anti-peptide antibodies (1 µg/mL) against MMP-212
and MMP-9.13 Normal serum was used for negative controls. After
30 minutes of incubation with primary antibody, slides were rinsed
with phosphate-buffered saline (PBS) for 5 minutes and then incu-
bated for an additional 20 minutes with the link reagent (biotiny-
lated anti-mouse or anti-rabbit IgG, 2-10 µg/mL; VectorLab,
Burlingame, Calif). After 1 minute of PBS rinse, the streptavidin
peroxidase label reagent (Biogenex, San Ramou, Calif) was
applied for 20 minutes at room temperature. Next, a final PBS
rinse was followed by 5 minutes of incubation with the chromagen
solution 3,3’-diaminobenzidine plus H2O2. Finally, the slides were
dehydrated, cleared, and mounted for viewing. All slides were
reviewed by a pathologist (L.P.) at 40× to 400× magnification.
We analyzed changes in variables from the initiation of bypass
to the termination of bypass with the Wilcoxon matched-pairs
signed-rank test. Relationships between variables were determined
with Spearman correlation. We decided to use nonparametric sta-
tistics because of the small sample size and the chance that one or
more of the contrast variables did not meet the assumptions of nor-
mality. All values are expressed as means ± SE.
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Results
We analyzed the initial 10 subjects for whom enzyme activ-
ities were measured separately from the subsequent 5
patients for whom tissue immunohistochemistry analysis
was performed. Our initial 10 patients were 66 ± 3.2 years
of age (range, 51-80 years). None of the patients experi-
enced serious complications from the operation. All recov-
ered uneventfully and were discharged home. Their length
of stay in the hospital was 6.7 ± 0.8 days (range, 5-14 days).
The mean time on CPB was 110 ± 5.4 minutes, with an aor-
tic crossclamp time of 80 ± 5.1 minutes. Table 1 summarizes
the measurements of routine clinical and hematologic param-
eters. Of note, there was an increase in white blood cell
counts (WBCs) after cardiac surgery. The decrease in hemo-
globin levels represents the routine clinical hemodilution
found after CPB. Other noted hemodynamic changes were
not of clinical significance.
The zymographic activity of pro-MMP-9 increased
(Figure 1) from initiation of bypass to termination of bypass
in cardiac tissue (Figure 1, A; P = .008) and plasma (Figure
1, B; P = .008). The zymographic activity of pro-MMP-2
was increased in cardiac tissue (201 ± 23 vs 310 ± 35 den-
sity units/mg protein, P < .001), but the increase in plasma
zymographic activity could have been caused by chance
alone (P > .2). The expression of TIMP-4 decreased (P =
.036) over the time period (Figure 2). The cardiac biopsy
specimens stained with hematoxylin and eosin did not
demonstrate important changes from initiation to termina-
tion of CPB. Detailed examination of the cardiac biopsy
specimens showed one specimen (a post-CPB sample) with
Figure 1. Pro-MMP-9 activity in right atrium (A) and in plasma (B)
is increased after bypass. Data are presented as means ± SE.
*Significant difference (P < .05) between the paired samples.
Insert is a representative patient sample analyzed by means of
zymography. Note that the activity of the 72-kd enzyme is indica-
tive of pro-MMP-2, and that of the 92-kd activity is indicative of
pro-MMP-9.
Figure 2. Decrease in TIMP-4 expression in right atrium after
bypass. Data are presented as means ± SE. *Significant difference
(P < .05) between the paired samples. Insert is a representative
patient sample analyzed by means of Western blotting. The activ-
ity at 29 kd is indicative of TIMP-4.
TABLE 1. Routine clinical and hematologic parameters
Preoperative Postoperative
Cardiac index (L · min–1 · m–2) 2.1 ± 0.2 2.2 ± 0.2
MAP (mm Hg) 86 ± 4.4 93 ± 4.1
Ppa (mm Hg) 23 ± 1.9 17 ± 1.3*
Pcwp 14 ± 1.3 11 ± 1.3*
SVR (dynes · s–1 · cm–5) 2798 ± 151 3069 ± 302
Hemoglobin (mg/dL) 111 ± 4.4 85 ± 5.1*
WCB (109 cells/L) 5.4 ± 0.5 9.0 ± 1.1*
CK-MB (% CK) 2.6 ± 1.7 3.6 ± 1.4
All data are presented as means ± SEM. MAP, Mean arterial blood pres-
sure; Ppa, pulmonary artery pressure; Pcwp, pulmonary capillary wedge
pressure; SVR, systemic vascular resistance; CK-MB, creatine phospho-
kinase MB fraction.
*Significant difference from initiation to termination of CPB (P < .05), as
determined with the Wilcoxon signed-rank test.
A
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a rare cluster of neutrophils within the myocardium within
an area of hemorrhage. All of the other biopsy specimens
show patchy interstitial fibrosis with little inflammatory cell
infiltrate. Using immunohistochemistry, we found that
MMP-2 and MMP-9 were expressed diffusely in cardiac
myocyte cytoplasm throughout the sample. The intensity of
staining clearly increased in myocytes from initiation to ter-
mination of CPB. Figure 3 illustrates the typical findings
observed in all the tissue sections visually inspected.
Total cardiac NOS activity before bypass was 4.46 ± 1.07
pmol citrulline/mg protein per minute; Ca2+-dependent
NOS activity accounted for 75% of total activity, and the
remaining activity was Ca2+ independent. Total NOS activ-
ity was increased (P = .018) up to 16.77 ± 4.86 pmol · mg–1
· min–1 from initiation to termination of bypass (Figure 4).
However, the ratio between Ca2+-dependent and Ca2+-inde-
pendent enzymes remained similar. We also evaluated the
distribution of cardiac NOS expression by means of
immunohistochemistry (Figure 5). In keeping with the
changes in enzyme activity, there was also a slight but clear-
ly distinguishable increase in tissue staining for both iNOS
and eNOS from initiation to termination of CPB.
There was a positive correlation between the activity of
tissue pro-MMP-9 and the tissue activity of NOS (P =
.0234, ρ = 0.82). We also examined correlations between the
measured enzyme activities and observed clinical parame-
ters. We found that tissue activity of pro-MMP-9 increased
with increasing duration of CPB time (P = .0092, ρ = 0.77).
We also found that WBCs increased with increasing plasma
pro-MMP-9 activity (P = .0412, ρ = 0.69). Similarly, neu-
Figure 3. Distribution of MMP expression in the right atrium. Staining for MMP-2 expression increases from onset
(A) and at termination (B) of CPB in a representative tissue sample. Similarly, staining for MMP-9 expression
increases at onset (C) and at termination (D) of CPB. Note that the tissue sections have been magnified at 160×.
Figure 4. Increased NOS activity in the right atrium. Data are pre-
sented as means ± SE. *Significant difference (P < .05) between
the paired samples.
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trophil counts increased with decreasing cardiac TIMP-4
activity (P = .048, ρ = 0.69).
Discussion
Myocardial function is transiently impaired after coronary
bypass surgery, and this impairment is often ascribed to the
procedure of CPB.14 The procedure of CPB includes multi-
ple components, including, but not limited to, the extracor-
poreal circulation, ischemia, reperfusion, and autotransfu-
sion of shed blood. This procedure increases release of
proinflammatory cytokines.10,11,15,16 Proinflammatory
cytokines (eg, tumor necrosis factor α, interleukin 1β, and
interleukin 6), in turn, are known to induce the generation of
mediators of inflammation. Nitric oxide is one major
inflammatory mediator induced by these cytokines, and its
overproduction has been associated with impaired cardiac
muscle performance.4,17 Myocardial NO levels and NOS
activity are increased after CPB in experimental animals,18
and we now confirm that myocardial NOS activity is also
increased in human patients undergoing coronary artery
bypass surgery.
At initiation of CPB, we found the presence of Ca2+-
independent iNOS in addition to the expected finding of
Ca2+-dependent eNOS in these human myocardial samples.
We also found that both myocardial Ca2+-dependent NOS
and Ca2+-independent NOS activities are increased during
the procedure of coronary artery bypass surgery. Our
immunohistochemical examination indicates that the
increased expression of eNOS and iNOS in myocytes could
account for the increased enzyme activities, and we do not
need to invoke the presence of inflammatory cell infiltration
as the source of these enzymes. If, as has been shown in ani-
mal studies, increased expression of myocyte NOS alters the
contractile properties of the myocardium,17 then our current
observations may account for some of the decreased con-
tractility seen after human CABG. Although in this study
we cannot ascribe which part of CABG surgery causes these
increases of NOS activity (ie, grafting versus CPB), our pre-
vious canine studies6 would suggest that the process of CPB
is most responsible.
MMP enzymes, such as MMP-2 and MMP-9, are also
induced by proinflammatory cytokines.19 Therefore we had
postulated that the activity of these MMPs should also
increase during CPB. Before CABG surgery, we found that
myocardium demonstrated measurable activities of both
MMP-2 and MMP-9. However, the tissue sections examined
by means of immunohistochemistry could only demonstrate
the presence of MMP-9 and did not reveal any MMP-2
immunoreactivity. The discrepancy between enzyme activi-
ty assay (zymography) and immmunohistologic technique
Figure 5. Distribution of NOS activity in the right atrium. There is a slight increase in staining for eNOS expression
from onset (A) to termination (B) of CPB. There is a similar slight increase of staining for iNOS expression from
onset (C) to termination (D) of CPB. Note that the tissue sections have been magnified at 160×.
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is best explained by a differential sensitivity of these assays
(ie, the enzyme assay is the more sensitive test). As with any
assay performed in vitro, zymography may not accurately
reflect the enzyme net activity in vivo. However, this assay
has been validated in numerous other conditions. We have
not only shown increased enzyme zymographic activity but
also demonstrated increased enzyme protein expression by
using immunohistochemistry. This increase in MMP activi-
ty is of biologic significance because we have concurrently
shown that the expression of the major myocardial inhibitor
of metalloproteinases, TIMP-4, is depressed after cardiac
surgery. Thus the zymographic activity of the MMPs is
increased, and at the same time, the activity of the inhibitor
of MMPs is decreased, resulting in relatively unopposed
MMP activity immediately after coronary artery bypass
surgery. There is as yet no direct correlation of changes in
MMP cardiac tissue activity with specific clinical outcomes
after human cardiac surgery. However, there is evidence
linking increased MMP activity with cardiac dysfunction in
other settings. Both human and animal studies have shown
that cardiac MMP-9 activity is increased7,20 and cardiac
TIMP-4 concentration is decreased7 in the setting of chron-
ic cardiomyopathy. Cardiac MMP-9 and MMP-2 activity
are acutely increased in rat and porcine models of ischemia-
reperfusion.10,21 Moreover, selective inhibition of MMP-2
decreased cardiac dysfunction caused by an ischemia-reper-
fusion injury.10 More recently, a synthetic inhibitor of MMP
activity has been shown to prevent acute lung injury in a
porcine model of lung injury induced by the combination of
CPB with endotoxin.22 Together, these studies suggest that
MMP-2 and MMP-9 are important effector enzymes
involved in the structural remodeling of the heart after treat-
ment-induced or disease-induced inflammatory reactions.
There are data from a wide variety of sources that other
MMPs may also play a role in the development of cardiac
dysfunction in other settings (eg, congestive heart failure).
However, because we focused our study on changes in
MMP-2, MMP-9, and TIMP-4, we cannot state whether
similar changes occur in other MMPs or TIMPs.
We were able to show that the increased MMP zymo-
graphic activity in the heart was not caused by the influx of
inflammatory cells. There was not histologic evidence of
inflammatory cell infiltration in the cardiac biopsy speci-
mens, with the exception of one slide showing neutrophils,
but only in the presence of hemorrhage. Instead, there is a
diffuse increase in MMP expression within myocytes, as
demonstrated immunohistochemically. The intramyocyte
localization of MMPs after CPB may have pathologic sig-
nificance. In patients with dilated cardiomyopathy, both
MMP-2 and MMP-9 are associated with sarcomeres, and
these MMPs23 were shown to digest the proteins that built
up the contractile apparatus of the myocyte. There is now
also evidence that overexpression of MMP-1 can also lead
to cardiac dysfunction through breakdown of the cardiac
extracellular matrix.24 Thus overactivity of MMPs in other
settings has been shown to disrupt normal myocyte struc-
tures and lead to cardiac dysfunction.
The adverse effects of CPB are not just restricted to the
heart but are systemic in nature. In effect, CPB can be con-
sidered as a form of inflammatory injury,3 the precise onset
of which is controlled (ie, the initiation of extracorporeal
flow). There is an almost universal decrement in pulmonary
function after CPB.25 In addition, there is frequently a dif-
fuse brain injury after CPB, with 3% of patients undergoing
cardiac surgery demonstrating significant intellectual deteri-
oration postoperatively, even in the absence of an overt
structural brain injury.26 We found that plasma pro-MMP-9
zymographic activity was immediately increased after CPB.
This supports our contention that the enzyme changes found
in the myocardium are markers of a more diffuse systemic
inflammatory process, but it is also possible that the heart
was the primary systemic source of this increased enzyme
activity. As pump time increased, so too did pro-MMP-9
zymographic activity, thus suggesting that this enzyme is
indeed associated with a more intense systemic insult.
Moreover, MMP-2 zymographic activity is elevated during
extracorporeal membrane oxygenation, and this release cor-
relates with platelet activation and injury.11 Thus MMPs
may also exert systemic effects in patients after various
forms of extracorporeal circulation.
We detected a complex interrelationship among MMP-9,
TIMP-4, and WBCs. Because cardiac surgery resulted in
increased WBCs, this correlated with an enhancement of
MMP-9 and reduction of TIMP-4 levels. Because no infil-
tration of inflammatory cells could be detected in the
myocardium, the relationship between WBCs and the
MMP-TIMP system could reflect the presence of systemic
inflammatory response initiated by cardiac surgery, of
which MMPs are an integral part.
The clinical significance of these findings is not yet
known. Our population sample is too small to make a mean-
ingful correlation with specific clinical outcomes (ie, mor-
tality, length of hospital stay, and organ function). We did
not recruit the requisite sample size to make these clinical
correlations because we did not know, a priori, that there
would be any measurable enzyme changes. However, there
are other studies suggesting that increased cardiac NOS
activity or increased cardiac MMPs zymographic activity
may be detrimental to heart function.4,5,17,27
In summary, we have found direct evidence of increased
activity of NOS, MMP-2, and MMP-9 after human cardiac
surgery. The clinical importance of these findings is uncer-
tain, but these findings may point to new treatments to
improve clinical outcomes of cardiac surgery.
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